Evidence map›Paper›PMID 36700224›Full record

ReviewFrontiers in immunology2022

Immune microenvironment infiltration landscape and immune-related subtypes in prostate cancer.

Wei Wu, Xin'an Wang, Wei Le, Chang Lu, Haopeng Li, Yaru Zhu, Xi Chen, Wenbin An, Chengdang Xu, Qiang Wu and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
9.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 42 citations in OpenAlex.

  1. A conserved eIF1ACell reports. Medicine · 2026
    Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Bolstering CD8Biology · 2025
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Wei WuDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Xin'an WangDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Wei LeDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Chang LuDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Haopeng LiDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Yaru ZhuDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Xi ChenDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Wenbin AnOrgan Transplantation Clinical Medical Center of Xiamen University, Department of Organ Transplantation, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Chengdang XuDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Qiang WuDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Licheng WangDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Tongji Hospital · CNTongji University · CNXiamen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The tumor microenvironment (TME) primarily comprises cancer cells, cancer-infiltrating immune cells, and stromal cells. The tumor cells alter the TME by secreting signaling molecules to induce immune tolerance. The immune cell infiltrating the TME influences the prognosis of patients with cancers. However, immune cell infiltration (ICI) in the TME of patients with prostate cancer (PC) has not yet been studied. Methods: In this study, we used Cell-type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT) and Estimation of Stromal and Immune cells in Malignant Tumors using Expression data (ESTIMATE) algorithms to identify three ICI clusters based on 1,099 genes associated with ICI in the TME. The patients were classified into three distinct ICI gene clusters based on overlapping differentially expressed genes in ICI clusters. Furthermore, the ICI scores were calculated using principal component analysis. Results: The results revealed that patients with high ICI scores had poor prognoses and reduced expression of immune-checkpoint genes and immune-related genes. Furthermore, the transforming growth factor-beta (TGF-β) and WNT-β signaling pathways were enriched in the high ICI score subgroup, which suggests that suppression of T cells could contribute to poor prognosis of patients with PC. A positive correlation was observed between the high-ICI-score subgroup and the high tumor mutation burden (TMB) value. Patients with low ICI scores could benefit from immunotherapy, indicating that the ICI score could be used to predict the efficacy of immunotherapeutic response. Conclusions: In summary, we provide a comprehensive overview of the landscape of ICI in PC, which could aid in designing the strategies for immunotherapy for patients with PC.

Indexed as

Prostatic NeoplasmsAlgorithmsBiological TransportGenes, OverlappingHumansImmune ToleranceMaleTumor Microenvironmentimmune cell infiltrationimmune checkpointprostate cancertumor microenvironmenttumor mutation burden

Identifiers

PMID36700224
PMCPMC9868452
OpenAlexW4313828095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.